STP @ 1.70

PDEX @ 2.52

IDRA @ 2.94

WTER @ .50

WTER @ .50 - looking good here...

OMER @ 12.83 - looking good, lets see if it can break and hold $13

OMER @ 12.88

CLNT @ 5.69

CLNT @ 5.69

TVIX @ 3.68 (*volatility index for any risk takers out there...)

nice call on MYEC!!

market not finished correcting IMO...be careful if any of you guys hold equities...

lol yea LUVE got dumped on..

REAC @ .0053

ENTB @ .0027

AEGY @ .0015

LUVE @ .35

EFLN @ .0012

lol

CGIX Share Structure:
Market Value1 $50,462,118 a/o May 23, 2013
Shares Outstanding 4,316,691 a/o May 08, 2013
Float Not Available
Authorized Shares 24,000,000 a/o Dec 31, 2012

Cancer Genetics to Present at Marcum MicroCap Conference:

*http://ir.cancergenetics.com/company-news/detail/234

RUTHERFORD, N.J.-- Cancer Genetics, Inc. (OTCQB: CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics, will present at the second annual Marcum MicroCap Conference on Thursday, May 30, 2013 at 2:30 p.m. ET at the Grand Hyatt New York in New York City.

The Marcum MicroCap Conference is dedicated to introducing investors to the best undiscovered companies under $500 million in market capitalization. In addition, the conference will showcase a number of panels that discuss issues that are of vital importance to small cap issuers and investors. The conference is expected to draw more than 1,000 attendees, including senior personnel from over 100 presenting public companies, leading institutional investors, directors, bankers and service providers to the microcap marketplace.

To learn more about the Marcum MicroCap Conference, visit http://marcumllp.com/MicroCap.

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. CGI has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.


Investor Relations
RedChip Companies, Inc.
Jon Cunningham, 800-733-2447, ext. 107
jon@redchip.com

Source: Cancer Genetics, Inc.

Released May 23, 2013

CGIX: Interview with the CEO

CGIX @ 11.68

thanks, SNTA is blessing my account at the moment $$$ ;)

PLPE @ .031 - UP 138%!!$$$ Nice DC

nice tradin'!!$$ :)

NTRR @ 2.70 - Mary Jane Potential

*will this be the next MDBX??

be careful with the low volume here

NTRR @ 2.70 - lookin good here, low SS

CERP @ .023

CLDS @ 1.27

OCTX @ 7.33

NTRR @ 5.28

CBAI @ .0048

CYTK @ 1.15

BVSN @ 8.72

BRZV @ .0195

VHGI @ .034

KBLB @ .112

DDCC @ .049